This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Universitätsklinikum Freiburg. Active years: 2014.
Company Filing History:
1 out of 3,688 
1 out of 36 
Years Active: 2014
Title: Klaus Mross: Innovator in Genotyping and Toxicity Prediction
Introduction
Klaus Mross is a notable inventor based in Freiburg, Germany. He has made significant contributions to the field of pharmacogenomics, particularly in the area of predicting adverse effects from microtubule-stabilizing agents. His work has implications for personalized medicine and improving patient outcomes.
Latest Patents
Klaus Mross holds a patent titled "ABCB1 genotyping to predict microtubule-stabilizing-agent-induced toxicity." This patent provides methods for identifying subjects who may be at an increased risk of developing adverse side effects from the administration of microtubule-stabilizing agents. The method involves determining whether a subject has an ABCB1 predictive polymorphism, which indicates a higher likelihood of experiencing toxicity. Specific polymorphisms mentioned include 2677G>T/A and 3435C>T. The patent also outlines methods for modifying therapy based on these predictive polymorphisms, along with the provision of kits and isolated nucleic acid molecules for use in these methods.
Career Highlights
Throughout his career, Klaus Mross has worked with prominent organizations, including the United States Department of Health and Human Services and Universitätsklinikum Freiburg. His research has focused on enhancing the safety and efficacy of cancer treatments through genetic insights.
Collaborations
Klaus has collaborated with esteemed colleagues such as Stephan Mielke and Alex Sparreboom. These partnerships have contributed to the advancement of research in pharmacogenomics and the development of innovative therapeutic strategies.
Conclusion
Klaus Mross is a pioneering inventor whose work in genotyping and toxicity prediction is shaping the future of personalized medicine. His contributions are vital for improving patient safety and treatment outcomes in the realm of cancer therapy.